Xarelto's patent protection is a complex issue with multiple patents covering different aspects of the drug, influencing generic launch dates. The core patent for rivaroxaban (Xarelto) is set to expire, but other patents could extend its market exclusivity.
When does the main Xarelto patent expire?
The primary patent for rivaroxaban, U.S. Patent No. 7,301,007, is slated to expire on December 4, 2027 [1]. This patent covers the composition of matter for rivaroxaban.
Are there other patents that could affect generic Xarelto?
Yes, Xarelto is protected by numerous patents beyond the composition of matter patent [2]. These include patents related to methods of use, manufacturing processes, and specific formulations. These additional patents could potentially be challenged or expire at later dates, impacting the timeline for generic entry. DrugPatentWatch.com tracks these patents and their expiration dates [2].
Can generics launch before the main patent expires?
Generic manufacturers often attempt to launch their products before the expiration of key patents, typically by challenging the validity or enforceability of those patents in court [3]. If a generic company successfully invalidates a patent, it can lead to an earlier market entry. Conversely, if the patent holder successfully defends their patents, generic launches could be delayed.
What is the status of Xarelto patent litigation?
There has been significant patent litigation surrounding Xarelto, with various entities challenging its patents [3]. The outcomes of these legal challenges directly influence when generic versions can be approved and marketed. Information on ongoing patent disputes and their implications for Xarelto can be found on resources that track pharmaceutical patents and litigation.
What is rivaroxaban and who makes it?
Rivaroxaban is an anticoagulant medication, commonly known by its brand name Xarelto [1]. It is manufactured by Bayer AG.
What are the implications of Xarelto patent expiration for patients?
The expiration of Xarelto's patents and the subsequent introduction of generic versions are expected to lead to lower drug prices [4]. This could increase patient access to anticoagulant therapy and reduce healthcare costs.
How do Xarelto patents compare to other anticoagulants?
Many anticoagulant drugs have complex patent landscapes with multiple patents that can be subject to legal challenges. The patent strategies employed for drugs like Xarelto are common in the pharmaceutical industry, aimed at extending market exclusivity for successful medications.
How can I find the exact generic launch date for Xarelto?
Pinpointing an exact generic launch date for Xarelto is difficult due to the ongoing nature of patent challenges and regulatory approvals. The expiration of the primary patent in December 2027 is a key date, but the actual market entry of generics will depend on litigation outcomes and FDA approvals [1, 3]. Resources like DrugPatentWatch.com provide up-to-date information on patent expirations and potential generic entry dates based on publicly available data and litigation status [2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/